Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1188 • 2019 ACR/ARP Annual Meeting
Novel PET-Coronary Flow Reserve Imaging to Assess for Coronary Microvascular Dysfunction in Systemic Lupus Erythematosus Compared to Subjects with Diabetes Mellitus and Controls
Cameron Speyer¹, Corine Sinnette ¹, Emma Stevens ¹, Hongshu Guan ², Courtney Bibbo ², Marcelo Di Carli ², Karen Costenbader ¹ and Elena Massarotti ², ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston
Background/Purpose: High risk of premature cardiovascular disease (CVD) among SLE patients is well documented, but the best means to detect the earliest stages of CVD…
Abstract Number: 1586 • 2019 ACR/ARP Annual Meeting
All-cause Hospitalizations and Mortality in Systemic Lupus Erythematosus in the US- results from a National Inpatient Database
Rashmi Dhital¹, Dilli Ram Poudel ², Ramesh Kumar Pandey ³ and Paras Karmacharya ⁴, ¹Reading Hospital ,PA, Shillington, PA, ²University of Pennsylvania, Philadelphia, ³Fox Chase Hospital, Philadelphia, ⁴Reading Hospital, Mayo Clinic, Rochester
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic multisystem autoimmune disorder with variable presentation. While several studies have outlined the risk factors for hospitalization and…
Abstract Number: 1624 • 2019 ACR/ARP Annual Meeting
Progression and Factors Associated with Damage Accrual in a SLE Inception Cohort of Hispanic Patients
Maria del Carmen Zamora Medina¹, Jessica Roldan Ortega ², Mario Cesar Ocampo Torres ³, Pilar Lara Reyes ¹, Alba Cicero Casarrubias ¹, Ivon Bautista Mejia ¹ and Juanita Romero-Diaz ⁴, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, Mexico, ²Monterrey Institute of Technology and Higher Education, MEXICO CITY, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, MEXICO CITY, ⁴Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico
Background/Purpose: The aims of our study were to determine the cumulative prevalence of damage at baseline, 5 years and 10 years of follow-up, to identify…
Abstract Number: 1914 • 2019 ACR/ARP Annual Meeting
Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Cristina Arriens¹, Quratul Raja ², Syed Ali Husain ², Bessy George ², Majid Abedi ³, Aviva Jacobs ⁴, Timothy Guyon ⁴, Hemani Wijesuriya ³, Teresa Aberle ⁵, Aikaterini Thanou ⁵, Stan Kamp ⁵, Susan R. Macwana ⁵, Eliza F. Chakravarty ¹, Joan T. Merrill ⁶, Judith James ¹, Robert Terbrueggen ⁴ and Joel Guthridge ¹, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³DxTerity Diagnostics Inc, Anaheim, CA, ⁴DxTerity Diagnostics Inc, Rancho Dominguez, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The interferon (IFN) signature in SLE is well established, distinguishing lupus patients from healthy controls. Additionally, within lupus patients, higher levels of IFN-responsive gene…
Abstract Number: 2127 • 2019 ACR/ARP Annual Meeting
Diagnosis of Inflammatory Rheumatic Diseases: Preliminary Approach by Urine Metabolomics
Judit Morello ¹, Sara M. Teixeira ¹, João Rodrigues ², Sara Maia ³, Atlas Sardoo ⁴, Rita Pinheiro Torres ⁵, Sofia A. Pereira ⁴, Jaime Branco ⁶, Alexandra Antunes ⁷ and Fernando Pimentel-Santos⁴, ¹Centro de Química Estrutural, Instituto Superior Técnico, Ulisboa, Lisboa, Portugal, ²Clarify Analytical, Évora, Portugal, ³CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon, Lisbon, Portugal, ⁴Centro de Estudos de Doenças Crónicas (CEDOC), Nova Medical School, Faculdade de Ciências Médicas, Universidade Nova de Lisboa, Lisboa, Portugal, lisboa, Portugal, ⁵Rheumatology Department, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental; CEDOC, NOVA Medical School, Faculdade de Ciências Médicas, Lisbon., Lisbon, Portugal, ⁶CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ⁷Centro de Química Estrutural, Instituto Superior Técnico, Ulisboa,, Lisboa, Portugal
Background/Purpose: Early diagnosis of inflammatory rheumatic diseases (IRD), as axial Spondyloarthritis (axSpA), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) represents in our days a…
Abstract Number: 2528 • 2019 ACR/ARP Annual Meeting
Effect of Additional Administration of HCQ on Pro-inflammatory Cytokine Expression, Especially in Lupus Nephritis
Risa Wakiya¹, Kiyo Ueeda ², Hiromi Shimada ², Shusaku Nakashima ¹, Mai Mahmoud Fahmy Mansour ¹, Mikiya Kato ¹, Taichi Miyagi ¹, Tomohiro Kameda ¹ and Hiroaki Dobashi ², ¹Kagawa University, Kagawa, ²Kagawa University, Kagawa, Japan
Background/Purpose: Hydroxychloroquine(HCQ) is recommended for all patients with SLE in EULAR recommendation 2019, however, there are not enough data about the effect of additional HCQ…
Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting
PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease
Ian Bruce¹, Alireza Nami ², Erik Schwetje ³, M Edward Pierson ⁴, Yen Lin Chia ⁵, Denison Kuruvilla ⁵, Gabriel Abreu ⁶, Raj Tummala ³ and Catharina Lindholm ⁶, ¹University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²Joint & Muscle Medical Care, Charlotte, NC, US, Charlotte, NC, ³AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, ⁴AstraZeneca, Gaithersburg, MD, US, Gaithersburg, MD, ⁵AstraZeneca, South San Francisco, CA, US, South San Francisco, CA, ⁶AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…
Abstract Number: 2812 • 2019 ACR/ARP Annual Meeting
A New Role for Selectins in Systemic Lupus Erythematosus
Marc SCHERLINGER¹, Vivien Guillotin ², Pierre Vacher ³, Vanja Sisirak ⁴, isabelle Douchet ⁴, Nathalie Merillon ⁴, Pierre Duffau ⁵, Estibaliz Lazaro ⁶, Emmanuel Ribeiro ⁷, Christophe Richez ⁸ and Patrick BLANCO ⁹, ¹CHU de Bordeaux, Immunoconcept, Bordeaux, France, ²CHU de Bordeaux, Bordeaux, France, ³INSERM ACTION U1218, Bordeaux, France, ⁴Immunoconcept, Bordeaux, France, ⁵Department of Internal Medicine and Clinical Immunology , Hôpital Saint-André, CHU de Bordeaux , Bordeaux , France., Bordeaux, Aquitaine, France, ⁶FHU ACRONIM, Department of Internal Medecine, Centre Hospitalier Universitaire, Bordeaux, France, Pessac, France, ⁷CHU de Bordeaux, Bordeaux, ⁸Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, ⁹CNRS-UMR 5164 - ImmunoConcEpt, Bordeaux University - Immunology and Immunogenetic Department Bordeaux University Hospital, Bordeaux, Aquitaine, France
Background/Purpose: In systemic lupus erythematosus (SLE), blood platelets have an activated phenotype, and express high levels of CD40L and P-selectin. Our group demonstrated that SLE…
Abstract Number: 82 • 2019 ACR/ARP Annual Meeting
Rab4A Increases Mitochondrial Oxidative Stress and Glutathione Disulfide Accumulation That Underlie Neurobehavioral Changes in Lupus-Prone Mice
Thomas Winans¹, Tamas Faludi ², Brandon Wyman ¹, Nick Huang ², Joshua Lewis ¹, Manuel Duarte ¹, Laurence Morel ³, Frank Middleton ² and Andras Perl ⁴, ¹Upstate Medical University, Syracuse, ²Upstate Medical University, Syracuse, NY, ³University of Florida, Gainesville, FL, ⁴SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: Background/Purpose The human GTPase HRES-1/Rab4 has been identified as a susceptibility locus for systemic lupus erythematosus (SLE) and is overexpressed in T cells of…
Abstract Number: 653 • 2019 ACR/ARP Annual Meeting
Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: A Distinct Disease Subset from Young-onset Lupus Nephritis
Kazuoto Hiramoto¹, Hironari Hanaoka ¹, Jun Kikuchi ¹, Shuntaro Saito ¹, Hiroshi Takei ², Tatsuhiro Oshige ¹, Noriyasu Seki ³, Hideto Tsujimoto ³, Yuko Kaneko ¹ and Tsutomu Takeuchi ¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, ³Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan
Background/Purpose: Elderly-onset SLE is recognized to be benign disease entity with a favorable nature course. Although late-onset lupus nephritis (LN), long interval between onset of…
Abstract Number: 860 • 2019 ACR/ARP Annual Meeting
Efficacy of Belimumab in Patients of Black Race with Systemic Lupus Erythematosus and High Disease Activity or Renal Manifestations
Luiz Sergio Guedes Barbosa ¹, Amit Saxena ², Ellen M Ginzler ³, Richard Furie⁴, David D'Cruz ⁵, Susan Burriss ⁶, Jennifer Gilbride ⁷, Michelle Miller ⁶, James Groark ⁶, David Roth ⁶ and Beulah Ji ⁸, ¹NUTEC - Núcleo de Terapia Especializada em Cancerologia, Cuiaba, Brazil, ²New York University School of Medicine, New York, NY, ³State University of New York Downstate Medical Center, Brooklyn, NY, ⁴Northwell Health, Great Neck, NY, ⁵The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom, ⁶GSK, Collegeville, PA, ⁷GSK, Stevenage, Hertfordshire, United Kingdom, ⁸GSK, Uxbridge, Middlesex, United Kingdom
Background/Purpose: Black patients have more severe SLE and more frequent lupus nephritis vs other racial groups. Efficacy and safety of intravenous (IV) belimumab was demonstrated…
Abstract Number: 1031 • 2019 ACR/ARP Annual Meeting
Expanded Circulating Peripheral Helper T Cells Are Associated with B Cell Differentiation in Systemic Lupus Erythematosus
Ayako Makiyama¹, Asako Chiba ², Daisuke Noto ¹, Goh Murayama ³, Tomohiro Mizuno ⁴, Taiga Kuga ⁵, Ken Yamaji ⁵, Naoto Tamura ⁵ and Sachiko Miyake ², ¹Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Autoreactive T-B cell interactions in lymphoid tissue have been thought to play a crucial role in the autoantibody production in systemic lupus erythematosus (SLE).…
Abstract Number: 1207 • 2019 ACR/ARP Annual Meeting
A Quality Improvement Intervention to Reduce 30-Day Hospital Readmission Rates Among Patients with Systemic Lupus Erythematosus
Emily Bowers¹, Melissa Griffith ¹, Elena Weinstein ¹, Duane Pearson ¹ and Jason Kolfenbach ¹, ¹University of Colorado Department of Rheumatology, Denver, CO
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic immune-mediated disease with significant morbidity and mortality that often requires inpatient hospitalization. SLE has one of the…
Abstract Number: 1590 • 2019 ACR/ARP Annual Meeting
Clinical and Sociodemographic Associates of Depression and Anxiety in Systemic Lupus Erythematosus
David Eldeiry¹, Moe Zandy ², Oshrat Tayer-Shifman ², Andrew Kwan ³, Sherief Marzouk ², Jiandong Su ², Kathleen Bingham ² and Zahi Touma ², ¹Royal College of Surgeons in Ireland, Dublin, Ireland, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Queens University, Kingston, ON, Canada
Background/Purpose: In our recent systematic review, we have shown a high prevalence for depression (35%) and anxiety (25.8%) in Systemic Lupus Erythematosus (SLE)1. A better…
Abstract Number: 1625 • 2019 ACR/ARP Annual Meeting
Severe Infection Prior to Diagnosis of Systemic Lupus Erythematosus (SLE) Is Associated with Disease-Specific Attributes and Long-Term Comorbidities
Yu Deng ¹, Anh Chung ², Abel Kho ¹, Yuan Luo ¹, Rosalind Ramsey-Goldman ² and Theresa Walunas², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL
Background/Purpose: Lupus is a systemic autoimmune disease whose mechanism of development is largely unknown. Prior infection is a suspected sentinel event that may trigger disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].